Foamix Pharmaceuticals Ltd. (FOMX) Stock Price, Forecast & Analysis
USA - NASDAQ:FOMX -
FOMX Key Statistics, Chart & Performance
The current stock price of FOMX is 2.99 null. In the past month the price decreased by -34.14%. In the past year, price decreased by -31.42%.
FOMX Latest News, Press Relases and Analysis
About FOMX
Company Profile
Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel.
Company Info
Foamix Pharmaceuticals Ltd.
2 HOLZMAN ST. WEIZMANN SCIENCE PARK
REHOVOT L3 76704
CEO: David Domzalski
Phone: 972-8931-6233
Foamix Pharmaceuticals Ltd. / FOMX FAQ
What does FOMX do?
Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel.
What is the stock price of Foamix Pharmaceuticals Ltd. today?
The current stock price of FOMX is 2.99 null. The price decreased by -7.72% in the last trading session.
Does Foamix Pharmaceuticals Ltd. pay dividends?
FOMX does not pay a dividend.
How is the ChartMill rating for Foamix Pharmaceuticals Ltd.?
FOMX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of Foamix Pharmaceuticals Ltd. (FOMX) based on its PE ratio?
Foamix Pharmaceuticals Ltd. (FOMX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.3).
FOMX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FOMX. When comparing the yearly performance of all stocks, FOMX turns out to be only a medium performer in the overall market: it outperformed 56.46% of all stocks.
FOMX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FOMX. FOMX may be in some trouble as it scores bad on both profitability and health.
FOMX Financial Highlights
Over the last trailing twelve months FOMX reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS increased by 34.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -21484.88% | ||
| ROA | -117.27% | ||
| ROE | N/A | ||
| Debt/Equity | 1.86 |